Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease

Background: Anti-integrin therapy is a new frontline strategy in the treatment of inflammatory bowel diseases (IBD). The anti-β7 integrin antibody etrolizumab is currently being investigated for safety and efficacy in Crohn’s disease (CD) and ulcerative colitis (UC) in several phase III trials. Mech...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Pharmacol
Main Authors: Lichnog, Charlotte, Klabunde, Sha, Becker, Emily, Fuh, Franklin, Tripal, Philipp, Atreya, Raja, Klenske, Entcho, Erickson, Rich, Chiu, Henry, Reed, Chae, Chung, Shan, Neufert, Clemens, Atreya, Imke, McBride, Jacqueline, Neurath, Markus F., Zundler, Sebastian
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2019
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6367223/
https://ncbi.nlm.nih.gov/pubmed/30774593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2019.00039
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados